WALLIS MOLCHEN to Humans
This is a "connection" page, showing publications WALLIS MOLCHEN has written about Humans.
Connection Strength
0.079
-
Overwhelmed to ownership: The lived experience of parents learning to become caregivers of children with tracheostomies. Int J Pediatr Otorhinolaryngol. 2022 Dec; 163:111364.
Score: 0.021
-
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011 Dec; 21(12):851-60.
Score: 0.005
-
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37.
Score: 0.005
-
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9.
Score: 0.005
-
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun; 140(7):1961-9.
Score: 0.005
-
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9.
Score: 0.005
-
A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 Mar-Apr; 51(2):137-48.
Score: 0.004
-
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
Score: 0.004
-
Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144.
Score: 0.003
-
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54(2):434-42.
Score: 0.002
-
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904.
Score: 0.002
-
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405.
Score: 0.002
-
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
Score: 0.002
-
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140(5):1490-500.e3.
Score: 0.002
-
Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials. 2009 Dec; 6(6):618-27.
Score: 0.002
-
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9.
Score: 0.002
-
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37.
Score: 0.002
-
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58.
Score: 0.002
-
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48.
Score: 0.002